Gena Wang
Stock Analyst at Barclays
(3.20)
# 1,078
Out of 5,147 analysts
237
Total ratings
45.16%
Success rate
1.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $19.00 | +321.05% | 8 | Feb 4, 2026 | |
| CYTK Cytokinetics | Assumes: Overweight | $87 | $62.22 | +39.83% | 6 | Jan 28, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $23.39 | +113.77% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.66 | +241.61% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $53.57 | -53.33% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $13.78 | +1.60% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.43 | +131.32% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $68.19 | -0.28% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $16.76 | +19.33% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $496.83 | -16.67% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $6.21 | +44.93% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $8.75 | +2.86% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $332.92 | +58.30% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $81.15 | +17.07% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $61.73 | +29.60% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.88 | +106.19% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $26.80 | -36.57% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $9.04 | +309.29% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $60.14 | -6.88% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $28.46 | -26.21% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $9.09 | +241.03% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.20 | +36.36% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $23.29 | -61.36% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $8.23 | +203.77% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.56 | +138.10% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $5.70 | +57.89% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.12 | +5,271.09% | 1 | Jan 6, 2017 |
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $19.00
Upside: +321.05%
Cytokinetics
Jan 28, 2026
Assumes: Overweight
Price Target: $87
Current: $62.22
Upside: +39.83%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $23.39
Upside: +113.77%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.66
Upside: +241.61%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $53.57
Upside: -53.33%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $13.78
Upside: +1.60%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.43
Upside: +131.32%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $68.19
Upside: -0.28%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $16.76
Upside: +19.33%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $496.83
Upside: -16.67%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $6.21
Upside: +44.93%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $8.75
Upside: +2.86%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $332.92
Upside: +58.30%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $81.15
Upside: +17.07%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $61.73
Upside: +29.60%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.88
Upside: +106.19%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $26.80
Upside: -36.57%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $9.04
Upside: +309.29%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $60.14
Upside: -6.88%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $28.46
Upside: -26.21%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $9.09
Upside: +241.03%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.20
Upside: +36.36%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $23.29
Upside: -61.36%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $8.23
Upside: +203.77%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.56
Upside: +138.10%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $5.70
Upside: +57.89%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.12
Upside: +5,271.09%